Home / Research library / Tesamorelin
Compound guide
Tesamorelin: what the research covers
The full forty-four residue GHRH sequence carrying a single fatty acid group at the amino terminus. It is the one compound in this part of the catalogue with controlled clinical literature behind its mechanism.
What Tesamorelin is
Where sermorelin solves the GHRH stability problem by being shorter, tesamorelin solves it by being decorated. The peptide is the complete forty-four residue human GHRH sequence, and a trans-3-hexenoyl group is attached to the amino terminus.
That small acyl addition sits exactly where dipeptidyl peptidase-4 would cut. Blocking the cleavage site extends circulating life well beyond sermorelin without altering the receptor-binding surface, so the compound remains a straightforward GHRH receptor agonist signalling through cyclic AMP in pituitary somatotrophs.
Three strategies therefore exist side by side in this class, and the distinction is worth holding onto when reading the literature: truncate the sequence, substitute the vulnerable residues, or shield them with an acyl group. Tesamorelin is the third.
Why the evidence base is unusual here
Most compounds in a research-peptide catalogue rest on cell culture and animal work. Tesamorelin does not. It carries controlled clinical trial data, and the finding that distinguishes it is a selective association with visceral rather than subcutaneous adipose tissue — a tissue-compartment specificity that does not fall out of the general growth hormone literature.
What that buys a laboratory is a reference point. When an experiment measures the growth hormone and IGF-1 axis after GHRH receptor agonism, tesamorelin provides a comparator whose downstream effects have been characterised in people as well as in culture. What it does not buy is any licence to extrapolate: the clinical work was done with defined preparations under medical supervision, and none of it transfers to a research-grade vial.
Research strands in the published literature cover GHRH receptor agonism and the GH and IGF-1 axis as usual, plus visceral adipose tissue biology, hepatic lipid handling and the comparative pharmacology of acylated against substituted analogues.
How Amino Club supplies it
Tesamorelin is supplied lyophilised in sealed vials as Tesamorelin, specified at 99% purity or better by HPLC with identity confirmed by mass spectrometry and released against the batch Certificate of Analysis. The lab testing page sets out the release sequence.
Identity confirmation does real work on this molecule. A forty-four residue peptide missing its hexenoyl group would be ordinary GHRH, chromatographically similar and functionally quite different, so mass is the check that separates them. Sealed vials tolerate ambient transit and are held below −18 °C for long-term storage; diluents are listed under reconstitution supplies.
Related reading
Tesamorelin belongs to the growth hormone research peptides group beside sermorelin, CJC-1295, ipamorelin and MK-677. Because its literature runs through adipose tissue, the metabolic research peptides hub is also relevant.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
Tesamorelin supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.